In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases

Shannon, Kevin; King, Anna; Warren, Christine; Phillips, Ian

doi:10.1128/aac.18.2.292

Cited by 67 publications

(33 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations were agreement with the findings of other researchers (Shannon et al, 1980;Wise et al, 1980). However, MIC for S.aureus is 32 μg/ml because S. aureus expresses an additional penicillin binding protein 2 (PBP2) with reduced affinity for beta-lactam antibiotics, therefore it has little bit higher MIC value (Taylor, 2003).…”

Section: Discussionsupporting

confidence: 82%

Pharmacokinetic study of sulbactomax

et al. 2010

View full text Add to dashboard Cite

-We have evaluated pharmacokinetics of a fixed dose combination (FDC) of ceftriaxone and sulbactam (2:1) or sulbactomax in eight healthy volunteers. A 1.5 g dose of sulbactomax, 1 g dose of ceftriaxone and 0.5 g sulbactam were given intravenously in a balanced two-ways cross-over study. Serially collected plasma sample was analyzed for ceftriaxone and sulbactam by high performance liquid chromatography (HPLC). The mean peaks of ceftriaxone and sulbactam concentrations in plasma were 152.06 ± 6.65 μg/ml and 21.32 ± 1.80 μg/ml, respectively and plasma half-lives for ceftriaxone and sulbactam were 5.2 ± 0.35 hr and 0.94 ± 0.038 hr, respectively. The AUC0-24 for ceftriaxone and sulbactam was 760.16 ± 27.68 μg.hr/ml and 20.74 ± 2.34 μg.hr/ml, respectively, with elimination rate constant of 0.133 ± 0.009 hr -1 and 0.732 ± 0.029 hr -1 , respectively. The kinetics of ceftriaxone and sulbactum did not change in combination as compared to the alone treatment. Also, concentration of the ceftriaxone after 24 hr is higher than the minimum inhibitory concentration (MIC) of the most of the gram positive and gram negative bacteria indicating that one dose in a day is sufficient to treat the disease caused by these organisms.

show abstract

Section: Discussionsupporting

confidence: 82%

Pharmacokinetic study of sulbactomax

et al. 2010

View full text Add to dashboard Cite

show abstract

“…All cephalosporins are inactive against Streptococcus faecalis (8,18). Ceftriaxone and cefotaxime are frequently inactive against Bacteroides fragilis, the anaerobe generally considered most resistant to beta-lactam antibiotics (1,8,18,23). Moxalactam, slightly more active against anaerobes than the other two drugs, has about the same level of activity against B. fragilis as cefoxitin (8,18).…”

Section: Methodsmentioning

confidence: 96%

“…The MIC90 of ceftriaxone and cefotaxime for S. aureus (penicillin G susceptible or resistant) are in the range of 3.1 to 6.3 ,ug/ml, whereas moxalactam is slightly less active (1,8,11,18,23). All three of the drugs have been clinically effective in treating S. aureus infections, but none is as active against this bacterium as are 6 the penicillinase-resistant semisynthetic penicillins or the first-generation cephalosporins (8).…”

Section: Methodsmentioning

confidence: 99%

“…The susceptibility of Staphylococcus epidermidis to ceftriaxone is variable, but the overall activity is poor (18). Ceftriaxone and cefotaxime are both very active against Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, and viridans group streptococci (1,8,11,18,23,29). Moxalactam, however, is significantly less active against streptococcal species, especially pneumococci and group B streptococci (8,18).…”

Section: Methodsmentioning

confidence: 99%

“…Unfortunately, post-therapy platelet counts were not available for most of these patients. An additional patient (patient 39, pneumonia and sickle cell anemia) had a platelet count of 495,000/mm3 on the 4th day of therapy which rose to 1,300,000/mm3 on day 8 and to 1,500,000/ mm3 on day 12 resistant strains reported (11,23). Ceftriaxone, cefotaxime, and moxalactam are only minimally active against P. aeruginosa, other Pseudomonas species, and Acinetobacter species (1,8,18,23,29).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Ceftriaxone: in vitro studies and clinical evaluation

Gnann¹,

Goetter²,

Elliott³

et al. 1982

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activity of ceftriaxone against 437 clinical isolates of gram-negative bacilli was determined. Ceftriaxone was found to have high in vitro activity against Enterobacteriaceae, with the exception of Enterobacter cloacae. Ceftriaxone was only minimally active against Pseudomonas aeruginosa and Acinetobacter calcoaceticus. We evaluated the clinical efficacy and toxicity of ceftriaxone in 55 adult patients. Bacterial infection was confirmed by the isolation of etiological bacteria in 30 patients. Infectious disorders treated included 10 pneumonias, 13 urinary tract infections, and 7 soft tissue or bone infections. Pathogens identified were 25 isolates of gram-negative bacilli, 5 isolates of Staphylococcus aureus, 5 isolates of pneumococci, and 4 isolates of other streptococci. The overall efficacy of ceftriaxone was excellent. The clinical cure rate was 93%, and the bacteriological cure rate was 93%. A total of 30 adverse reactions were noted in 22 of 55 patients receiving ceftriaxone, but only one necessitated discontinuation of treatment. Adverse effects frequently noted were elevated hepatic enzymes (16%), thrombocytosis (16%), and eosinophilia (8%). Ceftriaxone is an effective and well-tolerated antimicrobial agent that appears promising for the treatment of serious gram-negative bacillary infections.

show abstract

Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment

Baumgartner¹

1983

Archives of Internal Medicine

View full text Add to dashboard Cite

Ceftriaxone sodium, a new cephalosporin with a very broad spectrum of action and a very long serum half-life, was administered to 127 patients in the treatment of 133 severe infections at our institution in Lausanne, Switzerland. Eighty infections had previously been treated unsuccessfully with other antimicrobials to which the pathogens were most often resistant. Sixty-five episodes were treated with two daily injections until there was an improvement in the patient's clinical condition, while 67 infections were treated from the start by a single daily injection. The results in the two groups were similar. One hundred fifteen infections (86%) were cured or improved, ten (8%) did not respond to therapy or recurred, and eight (6%) were not evaluable. The treatment was well tolerated, even by the 18 patients who received the drug for more than four weeks. The administration of a single daily dose instead of four doses as with standard antibiotic regimens produced a saving of Sfr 84,000 (+42,000) in the 127 patients. The single daily dose also made it possible to treat 25 of the 127 severely ill patients as outpatients, with a saving of Sfr 388,500 (+195,000) with respect to the hospital costs that would have been incurred for the same time period.

show abstract

In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases

Cited by 67 publications

References 1 publication

Pharmacokinetic study of sulbactomax

Pharmacokinetic study of sulbactomax

Ceftriaxone: in vitro studies and clinical evaluation

Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment

Contact Info

Product

Resources

About